Viatris (VTRS) Return on Capital Employed Growth (1y) (2021 - 2026)
Viatris (VTRS) Return on Capital Employed Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 696.00 |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -507.00 |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -723.00 |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 89.00 |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 944.00 |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | 448.00 |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 1,195.00 |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | -679.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 944.00 |
| Dec 31, 2025 | -877.00 |
| Sep 30, 2025 | -790.00 |
| Jun 30, 2025 | -821.00 |
| Mar 31, 2025 | -1,041.00 |
| Dec 31, 2024 | -187.00 |
| Sep 30, 2024 | -314.00 |
| Jun 30, 2024 | -276.00 |
| Mar 31, 2024 | -157.00 |
| Dec 31, 2023 | -190.00 |
| Sep 30, 2023 | -157.00 |
| Jun 30, 2023 | -79.00 |
| Mar 31, 2023 | 89.00 |
| Dec 31, 2022 | 387.00 |
| Sep 30, 2022 | 579.00 |
| Jun 30, 2022 | 658.00 |
| Mar 31, 2022 | 525.00 |
| Dec 31, 2021 | 427.00 |
| Sep 30, 2021 | -555.00 |